https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Blood 2006 Mar;107(5):1818-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Blood 2006 Mar;107(5):1818-272005-11-01 00:00:002019-02-15 09:15:15Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-62005-11-01 00:00:002019-02-15 09:19:54Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-82005-10-28 00:00:002019-02-15 09:00:17Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-27 / Cancer Immunol. Immunother. 2006 Jan;55(1):63-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-27 / Cancer Immunol. Immunother. 2006 Jan;55(1):63-72005-10-27 00:00:002019-02-15 09:17:04Dendritic cell-based cancer immunotherapy targeting MUC-1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-25 / Blood 2006 Mar;107(5):1963-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-25 / Blood 2006 Mar;107(5):1963-92005-10-25 00:00:002019-02-15 09:15:16Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-78
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-782005-10-24 00:00:002023-01-23 10:35:21HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-13 / J. Clin. Invest. 2005 Nov;115(11):3265-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-13 / J. Clin. Invest. 2005 Nov;115(11):3265-752005-10-13 00:00:002019-02-15 09:15:19Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-07 / Hum. Immunol. 2005 Sep;66(9):938-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-07 / Hum. Immunol. 2005 Sep;66(9):938-492005-10-07 00:00:002019-02-15 09:25:40Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-03 / Br. J. Cancer 2005 Oct;93(7):749-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-03 / Br. J. Cancer 2005 Oct;93(7):749-562005-10-03 00:00:002019-02-15 09:24:20Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-212005-10-01 00:00:002019-02-15 09:25:41Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma
